Leach Jacob Steven 4

What Happened

• Jacob Steven Leach, President, CEO and Director of Dexcom (DXCM), received 8,310 shares on January 29, 2026 upon vesting of performance-based restricted stock units (PSUs).
• To cover tax withholding on the net settlement, 3,058 of those shares were withheld at an effective value of $73.36 per share, totaling $224,335. Net shares issued to Leach = 8,310 - 3,058 = 5,252 shares.
• Transaction codes: A = award/acquisition (PSU vesting); F = shares withheld to satisfy tax withholding (not an open-market sale).

Key Details

• Transaction date: 2026-01-29; Form 4 filed 2026-02-02 (timely — two business days after the transaction).
• Withheld shares: 3,058 shares at $73.36 each (total $224,335) to satisfy tax obligations. These withheld shares do not represent an open-market sale by the insider.
• Net new shares to Leach: 5,252 shares after withholding.
• Holdings/vesting detail (from footnote): the filing references 84,537 unvested restricted stock units (granted on various dates and vesting through 2028) plus 102 shares from the Employee Stock Purchase Plan (see footnote F3 for breakdown).
• Footnotes: F1 = issuance from March 8, 2023 PSUs upon achievement of performance conditions; F2 = withholding to cover tax obligations (not a sale); F3 = breakdown of unvested RSUs and ESPP shares.

Context

• This was a PSU vesting and net settlement for tax withholding (a routine compensation event), not an open-market purchase or sale that would signal immediate trading intent. Purchases by insiders tend to carry more informational weight; vesting/withholding events are common and driven by prior compensation awards and plan rules.